Agomab says STENOVA extension data for Crohn’s drug ontunisertib to be presented at UEG Week 2026

AGMB•2026-10-08

Agomab disclosed open-label extension results from its Phase 2a STENOVA study of ontunisertib in fibrostenosing Crohn’s disease; the data will be presented at UEG Week 2026 in Barcelona on Oct. 20.

Agomab says STENOVA extension data for Crohn’s drug ontunisertib to be presented at UEG Week 2026

1. Trial extension data

Related News

Children’s Place names Elizabeth A. LaPuma to board and audit committee

VerifyMe dismisses auditor MaloneBailey, hires RSM Cayman as new accountant

Byline Bancorp names Sean H. McGuire chief commercial banking officer

Byline Bancorp names Sean McGuire chief commercial banking officer effective Jan. 1, 2027

Aardvark Therapeutics director Zhang Zhongwei files initial beneficial ownership statement